Using site-directed mutagenesis, we have undertaken a study of a potential IGF-binding site in the C-terminal domain of rat IGFBP-5, lying close to or within a previously described heparin-binding domain (residues 201-218) in this protein. After analysis of binding activity using three different methods - ligand blotting, solution phase equilibrium binding and biosensor measurement of real-time on- and off-rates - we report that the mutation of two highly conserved residues within this region (glycine 203 and glutamine 209) reduces the affinity of the binding protein for both IGF-I and IGF-II, while having no effect on heparin binding. In addition, we confirm that mutation of basic residues within the heparin-binding domain (R201L, K202E, K206Q and R214A) results in a protein that has attenuated heparin binding but shows only a small reduction in affinity for IGF-I and -II. Previous findings have described the reduction in affinity of IGFBP-5 for IGFs that occurs after complexation of the binding protein with heparin or other components of the extracellular matrix (ECM) and have postulated that such an interaction may result in conformational changes in protein structure, affecting subsequent IGF interaction. Our data suggesting potential overlap of heparin- and IGF-binding domains argue for a more direct effect of ECM modulation of the affinity of IGFBP-5 for ligand by partial occlusion of the IGF-binding site after interaction with ECM.

This article has been cited by other articles:

				A. Mukherjee and P. Rotwein Insulin-Like Growth Factor-Binding Protein-5 Inhibits Osteoblast Differentiation and Skeletal Growth by Blocking Insulin-Like Growth Factor Actions Mol. Endocrinol., May 1, 2008; 22(5): 1238 - 1250. [Abstract] [Full Text] [PDF]

				A. M. Sorrell, J. H. Shand, E. Tonner, M. Gamberoni, P. A. Accorsi, J. Beattie, G. J. Allan, and D. J. Flint Insulin-like Growth Factor-binding Protein-5 Activates Plasminogen by Interaction with Tissue Plasminogen Activator, Independently of Its Ability to Bind to Plasminogen Activator Inhibitor-1, Insulin-like Growth Factor-I, or Heparin J. Biol. Chem., April 21, 2006; 281(16): 10883 - 10889. [Abstract] [Full Text] [PDF]

				G. J. Allan, E. Tonner, M. Szymanowska, J. H. Shand, S. M. Kelly, K. Phillips, R. A. Clegg, I. F. Gow, J. Beattie, and D. J. Flint Cumulative Mutagenesis of the Basic Residues in the 201-218 Region of Insulin-Like Growth Factor (IGF)-Binding Protein-5 Results in Progressive Loss of Both IGF-I Binding and Inhibition of IGF-I Biological Action Endocrinology, January 1, 2006; 147(1): 338 - 349. [Abstract] [Full Text] [PDF]

				J. Beattie, K. Phillips, J. H Shand, M. Szymanowska, D. J Flint, and G. J Allan Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein -3/5 (IGFBP-3/5) heparin axis J. Mol. Endocrinol., February 1, 2005; 34(1): 163 - 175. [Abstract] [Full Text] [PDF]

				S. J. Headey, D. W. Keizer, S. Yao, G. Brasier, P. Kantharidis, L. A. Bach, and R. S. Norton C-Terminal Domain of Insulin-Like Growth Factor (IGF) Binding Protein-6: Structure and Interaction with IGF-II Mol. Endocrinol., November 1, 2004; 18(11): 2740 - 2750. [Abstract] [Full Text] [PDF]

				J. H. Shand, J. Beattie, H. Song, K. Phillips, S. M. Kelly, D. J. Flint, and G. J. Allan Specific Amino Acid Substitutions Determine the Differential Contribution of the N- and C-terminal Domains of Insulin-like Growth Factor (IGF)-binding Protein-5 in Binding IGF-I J. Biol. Chem., May 9, 2003; 278(20): 17859 - 17866. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				H. J. Kock and A. E. Handschin Osteoblast Growth Inhibition by Unfractionated Heparin and by Low Molecular Weight Heparins: An in-vitro Investigation Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 251 - 255. [Abstract] [PDF]

				J. Hong, G. Zhang, F. Dong, and M. M. Rechler Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells J. Biol. Chem., March 15, 2002; 277(12): 10489 - 10497. [Abstract] [Full Text] [PDF]

				D. R. Clemmons Use of Mutagenesis to Probe IGF-Binding Protein Structure/Function Relationships Endocr. Rev., December 1, 2001; 22(6): 800 - 817. [Abstract] [Full Text] [PDF]

				E. M. Zimmermann, L. Li, Y. T. Hou, N. K. Mohapatra, and J. B. Pucilowska Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G1022 - G1029. [Abstract] [Full Text] [PDF]